Pigneur B, Seksik P, Viola S, et al. Natural history of Crohn’s disease: comparison between childhood- and adult-onset disease. Inflamm Bowel Dis. 2010;16(6):953–61. https://doi.org/10.1002/ibd.21152.

Article  PubMed  Google Scholar 

Duricova D, Burisch J, Jess T, Gower-Rousseau C, Lakatos PL, ECCO-EpiCom. Age-related differences in presentation and course of inflammatory bowel disease: an update on the population-based literature. J Crohns Colitis. 2014;8(11):1351–61. https://doi.org/10.1016/j.crohns.2014.05.006.

Article  PubMed  Google Scholar 

Kurowski JA, Milinovich A, Ji X, et al. Differences in biologic utilization and surgery rates in pediatric and adult Crohn’s disease: results from a large electronic medical record-derived cohort. Inflamm Bowel Dis. 2021;27(7):1035–44. https://doi.org/10.1093/ibd/izaa239.

Article  PubMed  Google Scholar 

Ahmed S, Alam S, Alsabri M. Health-related quality of life in pediatric inflammatory bowel disease patients: a narrative review. Cureus. 2022;14(9): e29282. https://doi.org/10.7759/cureus.29282.

Article  PubMed  PubMed Central  Google Scholar 

Sahn B, Markowitz J. The natural history of Crohn disease in children. In: Mamula P, Grossman A, Baldassano R, Kelsen J, Markowitz J, editors. Pediatric inflammatory bowel disease. Cham: Springer; 2017.

Google Scholar 

Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017;390(10114):2779–89. https://doi.org/10.1016/S0140-6736(17)32641-7.

Article  PubMed  Google Scholar 

Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570–83. https://doi.org/10.1053/j.gastro.2020.12.031.

Article  CAS  PubMed  Google Scholar 

Payen E, Neuraz A, Zenzeri L, et al. Adalimumab therapy in pediatric Crohn disease: a 2-year follow-up comparing “top-down” and “step-up” strategies. J Pediatr Gastroenterol Nutr. 2023;76(2):166–73. https://doi.org/10.1097/MPG.0000000000003643.

Article  CAS  PubMed  Google Scholar 

Hyams J, Walters TD, Crandall W, et al. Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn’s disease in children: REACH open-label extension. Curr Med Res Opin. 2011;27(3):651–62. https://doi.org/10.1185/03007995.2010.547575.

Article  CAS  PubMed  Google Scholar 

Jongsma MME, Aardoom MA, Cozijnsen MA, et al. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial. Gut. 2022;71(1):34–42. https://doi.org/10.1136/gutjnl-2020-322339.

Article  CAS  PubMed  Google Scholar 

Colman RJ, Lawton RC, Dubinsky MC, Rubin DT. Methotrexate for the treatment of pediatric Crohn’s disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2018;24(10):2135–41. https://doi.org/10.1093/ibd/izy078.

Article  PubMed  PubMed Central  Google Scholar 

Rosh JR. The current role of methotrexate in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2020;16(1):43–6.

PubMed  Google Scholar 

Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–95. https://doi.org/10.1056/NEJMoa0904492.

Article  CAS  PubMed  Google Scholar 

Chande N, Townsend CM, Parker CE, MacDonald JK. Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2016;10(10): CD000545. https://doi.org/10.1002/14651858.CD000545.pub5.

Article  PubMed  Google Scholar 

Shale M, Kanfer E, Panaccione R, Ghosh S. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut. 2008;57(12):1639–41. https://doi.org/10.1136/gut.2008.163279.

Article  PubMed  Google Scholar 

Hyams JS, Dubinsky MC, Baldassano RN, et al. Infliximab is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease. Gastroenterology. 2017;152(8): 1901–14.e3. https://doi.org/10.1053/j.gastro.2017.02.004.

Article  Google Scholar 

Spencer EA, Dubinsky MC. Precision medicine in pediatric inflammatory bowel disease. Pediatr Clin North Am. 2021;68(6):1171–90. https://doi.org/10.1016/j.pcl.2021.07.011.

Article  PubMed  Google Scholar 

Hyams JS, Turner D, Cohen SA, et al. Pharmacokinetics, safety and efficacy of intravenous vedolizumab in paediatric patients with ulcerative colitis or Crohn’s disease: results from the phase 2 HUBBLE Study. J Crohns Colitis. 2022;16(8):1243–54. https://doi.org/10.1093/ecco-jcc/jjac036.

Article  PubMed  PubMed Central  Google Scholar 

Atia O, Shavit-Brunschwig Z, Mould DR, et al. Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study. Lancet Gastroenterol Hepatol. 2023;8(1):31–42. https://doi.org/10.1016/S2468-1253(22)00307-7.

Article  PubMed  Google Scholar 

Schwartz DA, Peyrin-Biroulet L, Lasch K, Adsul S, Danese S. Efficacy and safety of 2 vedolizumab intravenous regimens for perianal fistulizing Crohn’s disease: ENTERPRISE Study. Clin Gastroenterol Hepatol. 2022;20(5): 1059–67.e9. https://doi.org/10.1016/j.cgh.2021.09.028.

Article  CAS  Google Scholar 

Sandborn WJ, Panes J, Danese S, et al. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn’s disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2023;8(1):43–55. https://doi.org/10.1016/S2468-1253(22)00303-X.

Article  PubMed  Google Scholar 

Dayan JR, Dolinger M, Benkov K, et al. Real world experience with ustekinumab in children and young adults at a tertiary care pediatric inflammatory bowel disease center. J Pediatr Gastroenterol Nutr. 2019;69(1):61–7. https://doi.org/10.1097/MPG.0000000000002362.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sandborn WJ, Rebuck R, Wang Y, et al. Five-year efficacy and safety of ustekinumab treatment in Crohn’s disease: the IM-UNITI Trial. Clin Gastroenterol Hepatol. 2022;20(3): 578–90.e4. https://doi.org/10.1016/j.cgh.2021.02.025.

Article  CAS  Google Scholar 

Rosh JR, Turner D, Griffiths A, et al. Ustekinumab in paediatric patients with moderately to severely active Crohn’s disease: pharmacokinetics, safety, and efficacy results from UniStar, a phase 1 study. J Crohns Colitis. 2021;15(11):1931–42. https://doi.org/10.1093/ecco-jcc/jjab089.

Article  PubMed  PubMed Central  Google Scholar 

Rosh JR, Lerer T, Markowitz J, et al. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn’s disease. Am J Gastroenterol. 2009;104(12):3042–9. https://doi.org/10.1038/ajg.2009.493.

Article  CAS  PubMed  Google Scholar 

Sands BE, Irving PM, Hoops T, et al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn’s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022;399(10342):2200–11. https://doi.org/10.1016/S0140-6736(22)00688-2.

Article  CAS  PubMed  Google Scholar 

Danese S, Vermeire S, D’Haens G, et al. Treat to target versus standard of care for patients with Crohn’s disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial. Lancet Gastroenterol Hepatol. 2022;7(4):294–306. https://doi.org/10.1016/S2468-1253(21)00474-X.

Article  PubMed  Google Scholar 

Yerushalmy-Feler A, Pujol-Muncunill G, Martin-de-Carpi J, et al. Safety and potential efficacy of escalating dose of ustekinumab in pediatric Crohn disease (the Speed-up Study): a multicenter study from the Pediatric IBD Porto Group of ESPGHAN. J Pediatr Gastroenterol Nutr. 2022;75(6):717–23. https://doi.org/10.1097/MPG.0000000000003608.

Article  CAS  PubMed  Google Scholar 

Bermejo F, Jimenez L, Algaba A, et al. Re-induction with intravenous ustekinumab in patients with Crohn’s disease and a loss of response to this therapy. Inflamm Bowel Dis. 2022;28(1):41–7. https://doi.org/10.1093/ibd/izab015.

Article  PubMed  Google Scholar 

Attauabi M, Burisch J, Seidelin JB. Efficacy of ustekinumab for active perianal fistulizing Crohn’s disease: a systematic review and meta-analysis of the current literature. Scand J Gastroenterol. 2021;56(1):53–8. https://doi.org/10.1080/00365521.2020.1854848.

Article  CAS  PubMed  Google Scholar 

Ruemmele FM, Rosh J, Faubion WA, et al. Efficacy of adalimumab for treatment of perianal fistula in children with moderately to severely active Crohn’s disease: results from IMAgINE 1 and IMAgINE 2. J Crohns Colitis. 2018;12(10):1249–54. https://doi.org/10.1093/ecco-jcc/jjy087.

Article  PubMed  PubMed Central  Google Scholar 

Papamichael K, VandeCasteele N, Jeyarajah J, Jairath V, Osterman MT, Cheifetz AS. Higher postinduction infliximab concentrations are associated with improved clinical outcomes in fistulizing Crohn’s disease: an ACCENT-II post hoc analysis. Am J Gastroenterol. 2021;116(5):1007–14. https://doi.org/10.14309/ajg.0000000000001111.

Article  CAS  PubMed  PubMed Central  Google Scholar 

D’Haens G, Panaccione R, Baert F, et al. Risankizumab as induction therapy for Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399(10340):2015–30. https://doi.org/10.1016/S0140-6736(22)00467-6.

Article  CAS  PubMed  Google Scholar 

Ferrante M, Panaccione R, Baert F, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn’s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022;399(10340):2031–46. https://doi.org/10.1016/S0140-6736(22)00466-4.

Article